Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Differences In Outcomes Of Patients With Congestive Heart Failure Prescribed Celecoxib, Rofecoxib, Or Non-Steroidal Anti-Inflammatory Drugs: Population Based Study

Marie Hudson, Hugues Richard and Louise Pilote
BMJ: British Medical Journal
Vol. 330, No. 7504 (Jun. 11, 2005), pp. 1370-1373
Published by: BMJ
Stable URL: http://www.jstor.org/stable/25459904
Page Count: 4
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Differences In Outcomes Of Patients With Congestive Heart Failure Prescribed Celecoxib, Rofecoxib, Or Non-Steroidal Anti-Inflammatory Drugs: Population Based Study
Preview not available

Abstract

Objectives To compare the risk of death and recurrent congestive heart failure in elderly patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs (NSAIDs) and to determine whether there are class differences between celecoxib and rofecoxib. Design Population based retrospective cohort study. Setting Databases of hospital discharge summaries and prescription drug claims in Quebec. Participants 2256 patients aged 66 or more prescribed celecoxib, rofecoxib, or a NSAID after an index admission for congestive heart failure between April 2000 and March 2002. Main outcome measures Time to all cause death and recurrent congestive heart failure, combined and separately. Results The risk of death and recurrent congestive heart failure combined was higher in patients prescribed NSAIDs or rofexocib than in those prescribed celecoxib (hazard ratio 1.26, 95% confidence interval 1.00 to 1.57 and 1.27, 1.09 to 1.49, respectively). The findings were similar when the outcomes were assessed separately. In pairwise analysis, the risks of death and recurrent congestive heart failure, combined and separate, were similar between patients prescribed NSAIDs and rofecoxib. Conclusions Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure. Differences were found among cyclo-oxygenase-2 inhibitors.

Page Thumbnails

  • Thumbnail: Page 
1370
    1370
  • Thumbnail: Page 
1371
    1371
  • Thumbnail: Page 
1372
    1372
  • Thumbnail: Page 
1373
    1373